

Opto Circuits' subsidiary Eurocor's next-gen DEB products gain wide interest amongst United States interventional cardiologists

**Washington| Bengaluru
September 27, 2010**

Opto Circuits (India) Ltd.'s subsidiary Eurocor GmbH's drug-eluting balloon (DEB) devices DIOR® and FREEWAY®, targeted at the treatment of obstructed arteries in both coronary and peripheral indications, have received an extremely high level of interest in this year's TCT (Transcatheter Cardiovascular Therapeutics) event in Washington DC, United States.

Eurocor hosted a breakfast symposium which focused on the clinical advantages of the revolutionary line of drug-eluting balloons (DEB) and their clinical efficacy. Topics covered were pre-clinical programs and updates on on-going clinical studies and the global Valentine® registry which enrolled over 300 patients in a study of DIOR® DEB earlier this year.

Speakers at the standing-room only symposium were Massimo Sangiorgi, MD of Modena, Italy, Dr. Karl-Ludwig Schulte, MD, PhD of the Vascular Center in Berlin, Germany, Antonio Serra, MD from the Hospital del Mare in Barcelona, Spain and Dr. Ron Waksman, MD of Washington Hospital in Washington DC as well as others.

Treatments with drug-eluting balloon (DEB) devices were amongst the much discussed and widely-covered topics of the conference. Feedback and comments in various clinical sessions proved that DEB is now seen as the most exciting innovation in the treatment of arterial disease, since the introduction of the drug eluting stent in the last decade.

"We are pleased to hear that our vision for the Eurocor pipeline is being validated by global opinion leaders", said Sreerangan Kurup, Managing Director, Eurocor GmbH. "The clinical data accumulated to-date clearly shows that Eurocor's DIOR® and FREEWAY® DEB products produce very favorable clinical results in the treatment of de-novo lesions as well as in-stent restenosis and are also very well suited for small vessel and bifurcated lesions treatment. We are in the process of commencing several new clinical studies as well as an even larger global registry for our DEB products and are well on the way to the accumulation of 1,000+ patient clinical data in support of the efficacy of our DEB devices", he concluded.

Eurocor is planning to unveil the first 6 month follow-up results of the global Valentine® DEB registry during the upcoming 2011 CRT event, which will be held in February, also in Washington DC.

Published clinical data till date has clearly shown that drug-eluting balloon devices are safe and very effective in the treatment of arterial diseases. The Eurocor devices offer superior performance due to their innovative coating technology and their ability to deliver the therapeutic compound more consistently and with lower long-term safety risks as compared to drug-eluting stents.

About DIOR®

DIOR® is a drug (paclitaxel)-eluting breakthrough balloon dilatation catheter developed by scientists at Eurocor and used by hundreds of interventional cardiologists across the world. It can be effectively used in patients with in-stent restenosis, bifurcation lesions and lesions in small vessels.

DIOR is manufactured out of Europe and is sold in Europe, Asia and Latin America. Eurocor was the first to receive a CE approval for a DEB and the first to launch such a device into world markets.

More information available at: http://www.eurocor.de/products/dior/product_information/

About FREEWAY®

Freeway® is a novel peripheral-usage Percutaneous Transluminal Angioplasty (PTA) balloon catheter which is coated with the drug, Paclitaxel. The Freeway balloon provides two medical treatment functions: a) it is used to dilate the arterial lesion to re-canalize the lumen up to its reference diameter and b) the highly lipophilic Paclitaxel, coated onto the balloon surface, allows for a rapid cellular uptake from the balloon into the diseased arterial segment.

More information available at: http://www.eurocor.de/products/freeway_014/product_information/

About TCT

TCT (Transcatheter Cardiovascular Therapeutics) is the world's largest educational meeting specializing in interventional cardiovascular medicine. For more than 20 years, TCT has been the center of new cutting-edge educational content. This symposium is designed for interventional cardiologists, radiologists, clinical cardiologists, basic scientists, vascular medicine specialists, surgeons, nurses, cat lab technicians, and other health care professionals with a special interest in the field of interventional and vascular medicine.

More information available at: <http://www.tctconference.com/>